- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02723994
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Expanded Access
Contacts and Locations
Study Contact
- Name: Incyte Corporation Call Center
- Phone Number: 1.855.463.3463
Study Locations
-
-
-
Hamilton, Canada, L8V 5C2
- McMaster University Medical Centre
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta'S Children Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6G1R8
- BC Children's Hospital
-
-
Ontario
-
Toronto, Ontario, Canada, 94611
- The Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- CHU Sainte-Justine
-
Montreal, Quebec, Canada, H4A 3J1
- McGill University Health Centre/Glen Site/Cedars Cancer Centre
-
-
-
-
-
San Juan, Puerto Rico, 00912
- San Jorge Childrens Hospital
-
San Juan, Puerto Rico, 00930
- University Pediatric Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- The Childrens Hospital of Alabama
-
-
Arizona
-
Phoenix, Arizona, United States, 85016-7710
- Phoenix CHildren's Hospital
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Arkansas Childrens Hospital
-
-
California
-
Fontana, California, United States, 92335
- Kaiser Permanente
-
Loma Linda, California, United States, 92350
- Loma Linda University Cancer Center
-
Long Beach, California, United States, 90806
- Miller Childrens Hospital Pharmacy
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, United States, 90027
- Southern California Permanente Medical Group
-
Los Angeles, California, United States, 90027
- Kaiser Foundation Health Plan
-
Madera, California, United States, 93636-8762
- Valley Childrens Hospital
-
Orange, California, United States, 92868
- Choc Children Hospital
-
Palo Alto, California, United States, 94304
- Lucille Packard Childrens Hospital
-
San Diego, California, United States, 92123
- Rady Children's Hospital - San Diego
-
San Diego, California, United States, 92111
- Kaiser Permanente
-
San Francisco, California, United States, 94158
- Ucsf Pediatric Oncology
-
Santa Fe Springs, California, United States, 90670
- Kaiser Permanente Downey
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Connecticut Children'S Medical Ctr
-
New Haven, Connecticut, United States, 06510
- Smilow Cancer Center - Yale
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Alfred I. DuPont Hospital for Children
-
-
Florida
-
Fort Myers, Florida, United States, 33908
- Childrens Hospital of Southwest Florida
-
Hollywood, Florida, United States, 33021
- Joe Dimaggio Children Hospital
-
Jacksonville, Florida, United States, 32207
- Nemours Childrens Clinic
-
Jacksonville, Florida, United States, 32209
- University of Florida Health Shands Hospital
-
Orlando, Florida, United States, 32803
- Florida Hospital Orlando
-
Orlando, Florida, United States, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, United States, 32504
- Nemours Childrens Clinic
-
Saint Petersburg, Florida, United States, 33701
- All Childrens Hospital
-
Tampa, Florida, United States, 33607
- St Josephs Childrens Hospital Tampa
-
West Palm Beach, Florida, United States, 33407
- Saint Marys Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322-1060
- Egleston Children'S Health
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann & Robert H. Lurie Children's Hospital
-
Maywood, Illinois, United States, 60153-3328
- Loyola University Medical Center
-
Springfield, Illinois, United States, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, United States, 46260
- St Vincent Hospital
-
-
Iowa
-
Des Moines, Iowa, United States, 50309
- Blank Childrens Hospital
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospital and Clinics
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
Louisville, Kentucky, United States, 40202
- Kosair Childrens Hospital
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic
-
-
Maine
-
Scarborough, Maine, United States, 04074
- Maine Center for Cancer Medicine
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, United States, 21287-7049
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Boston Children'S
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Cs Mott Childrens Hospital
-
Grand Rapids, Michigan, United States, 49503
- Helen Devos Childrens Hosp
-
Lansing, Michigan, United States, 48912
- Michigan State University
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Children's Hospitals and Clinics of Minnesota
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- The Children'S Mercy Hospital Outpatient
-
Saint Louis, Missouri, United States, 63130
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Children's Hospital & Medical Center
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- Alliance for Childhood Diseases
-
Las Vegas, Nevada, United States, 89109
- Children'S Center For Cancer & Blood Dis
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, United States, 07962
- Morristown Medical Center
-
New Brunswick, New Jersey, United States, 08901
- Rutgers Cancer Institute of NJ
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, United States, 07503
- St Josephs Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico Hospital
-
-
New York
-
Albany, New York, United States, 12208
- Albany Medical College
-
Buffalo, New York, United States, 14263
- Roswell Park Comprehensive Cancer Center
-
New Hyde Park, New York, United States, 11040
- Cohen Children's Medical Center
-
New York, New York, United States, 10021
- Weill Cornell Medical College
-
New York, New York, United States, 10032
- Nyu Clinical Cancer Center
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
Valhalla, New York, United States, 10595
- New York Medical College
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Childrens Hospital Medical Center
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, United States, 44106
- Rainbow Babies & Children Hosp
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, United States, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, United States, 43606
- Toledo Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, United States, 97227
- Legacy Emanuel Hospital and Health Center
-
Portland, Oregon, United States, 97239
- Doernbecher Childrens Hospital
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033-2360
- Penn State Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15224
- Childrens Hospital of Pittsburgh
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Hasbro Childrens Hospital
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, United States, 78723
- Dell Childrens Medical Center of Central Texas
-
Corpus Christi, Texas, United States, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Dallas, Texas, United States, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, United States, 79905
- El Paso Children'S Hospital Corporation
-
Houston, Texas, United States, 77030
- Texas Childrens Hospital
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Cente
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Primary Children's Hospital
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Children'S Hospital of the
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
Spokane, Washington, United States, 99204
- Providence Sacred Heart Medical Center & Children's Hospital
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54301
- St Vincent Hospital
-
Milwaukee, Wisconsin, United States, 53226
- Medical College Of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eligible for study when participant is 1 year to 21 years at the time of diagnosis
- Eligible Ages in Canada; 2 years to 21 years
De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present at diagnosis:
- Age ≥ 10 years
- White blood cell (WBC) ≥ 50 × 10^3/μL
- CNS3 leukemia at diagnosis
- Systemic steroid pretreatment without presteroid WBC documentation
Diagnostic bone marrow or peripheral blood sample must have gene expression profiling and downstream genetic testing performed by submitting diagnostic specimens under the COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study. Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested by low density microarray testing at the COG ALL reference laboratory or TriCore laboratory at the University of New Mexico AND must contain 1 of the following genetic lesions: (determined at COG ALL reference laboratories, or equivalent CAP/CLIA-certified laboratories approved by the medical monitor:
- CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+)
- CRLF2 rearrangement without JAK mutation
- Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions, IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as determined by a COG ALL Reference Laboratory
- Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in Study AALL1131 or its successor study, or as per the institutional standard of care for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
- Male and female subjects of reproductive non childbearing potential or willing to take appropriate precautions to avoid pregnancy or fathering a child for the duration of study participation
Exclusion Criteria:
- Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception of hydroxyurea or steroid pretreatment
- Trisomy 21 (Down syndrome)
- BCR-ABL1-rearranged (Ph+) ALL
- Calculated creatinine clearance or radioisotope glomerular filtration rate < 70 mL/min/1.73 m^2
- Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age
- Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
- History or evidence of cirrhosis
- Platelet count < 75 × 10^3/μL
- Absolute neutrophil count (ANC) < 750/μL
- Positive screen for hepatitis B or C
- Known human immunodeficiency virus infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ruxolitinib in combination with chemotherapy
|
In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design.
The established recommended starting dose will be taken forward into Part 2.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiograms
Time Frame: Part 1: AEs assessed from screening through up to 30 days after the last dose of study drug, expected to be 26 months (females) or 38 months (males)
|
Part 1: AEs assessed from screening through up to 30 days after the last dose of study drug, expected to be 26 months (females) or 38 months (males)
|
Part 2: Efficacy of ruxolitinib in combination with chemotherapy as measured by Event-free survival, defined as the percentage of patients alive without relapse, progression, or death at 3 years from study Day 1
Time Frame: Part 2: assessed at 3 years
|
Part 2: assessed at 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability of the combination treatment for subjects beginning treatment at the recommended dose for Part 2, as assessed by AEs, vital signs, clinical laboratory tests, and echocardiograms
Time Frame: AEs assessed from screening through up to 30 days after the last dose of study treatment, expected to be 26 months (females) or 38 months (males)
|
AEs assessed from screening through up to 30 days after the last dose of study treatment, expected to be 26 months (females) or 38 months (males)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Sarah Tasian, MD, Children's Hospital of Philadelphia, Philadelphia, PA
- Study Director: Albert Assad, MD, Incyte Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protective Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Micronutrients
- Antibiotics, Antineoplastic
- Vitamins
- Reproductive Control Agents
- Antidotes
- Vitamin B Complex
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Dexamethasone
- Cyclophosphamide
- Leucovorin
- Levoleucovorin
- Prednisone
- Doxorubicin
- Cytarabine
- Methotrexate
- Vincristine
- Asparaginase
- Mercaptopurine
- Thioguanine
- Pegaspargase
Other Study ID Numbers
- INCB 18424-269
- AALL1521 (Other Identifier: Children's Oncology Group)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
Clinical Trials on Methotrexate
-
University Hospital, MontpellierPfizer; Hôpital CochinCompletedRheumatoid ArthritisFrance, Monaco
-
Nicolaus Copernicus UniversityCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Unknown
-
Hee Young JuNot yet recruitingLymphoblastic Leukemia in Children
-
PfizerCompletedRheumatoid ArthritisUnited States, Mexico, Argentina, Chile, Croatia, Czech Republic, Hungary, Poland, Puerto Rico
-
PfizerCompletedRhematoid ArthritisSpain, United Kingdom, United States, Korea, Republic of, Poland, Israel, Australia, Taiwan, Thailand, South Africa, Bulgaria, Estonia, Latvia, Philippines, Canada, Romania, Russian Federation, Turkey, Mexico, Bosnia and Herzegovina and more
-
Cairo UniversityCompleted
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
-
CHA UniversityCompleted
-
Mitsubishi Tanabe Pharma CorporationCompleted